Real-world evidence used to compare tolerability of PARP inhibitors for ovarian cancer

• Patients were identified with ovarian cancer who initiated olaparib, niraparib, or rucaparib between January 1, 2017, and May 31, 2019
• A total of 813 patients were included in the study; 303 received olaparib, 348 received niraparib, and 162 received rucaparib
• Differences were observed between the licensed PARP inhibitors in the risk of experiencing any clinical event of interest also in the likelihood of dose modifications and the ability to receive continuous therapy

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: APR2021BS001